Literature DB >> 22353758

Sustained recreational use of ecstasy is associated with altered pre and postsynaptic markers of serotonin transmission in neocortical areas: a PET study with [¹¹C]DASB and [¹¹C]MDL 100907.

Nina Bl Urban1, Ragy R Girgis, Peter S Talbot, Lawrence S Kegeles, X Xu, W Gordon Frankle, Carl L Hart, Mark Slifstein, Anissa Abi-Dargham, Marc Laruelle.   

Abstract

3,4-Methylenedioxymethamphetamine (MDMA), the main psychoactive component of the recreational drug ecstasy, is a potent serotonin (5-HT) releaser. In animals, MDMA induces 5-HT depletion and toxicity in 5-HT neurons. The aim of this study was to investigate both presynaptic (5-HT transporter, SERT) and postsynaptic (5-HT(2A) receptor) markers of 5-HT transmission in recently abstinent chronic MDMA users compared with matched healthy controls. We hypothesized that MDMA use is associated with lower SERT density and concomitant upregulation of 5-HT(2A) receptors. Positron emission tomography studies using the SERT ligand [¹¹C]DASB and the 5-HT(2A) receptor ligand [¹¹C]MDL 100907 were evaluated in 13 current and recently detoxified MDMA users and 13 matched healthy controls. MDMA users reported a mean duration of ecstasy use of 8 years, regular exposure, and at least 2 weeks of abstinence before the scans. SERT and 5-HT(2A) receptor availability (binding potential, BP(ND)) were analyzed with a two-tissue compartment model with arterial input function. Current recreational MDMA use was significantly associated with lower SERT BP(ND) and higher 5-HT(2A) receptor BP(ND) in cortical, but not subcortical regions. Decreased SERT BP(ND) was regionally associated with upregulated 5-HT(2A) receptor BP(ND). In light of the animal literature, the most parsimonious interpretation is that repeated exposure to MDMA in humans, even in moderate amounts, leads to damage in 5-HT neuron terminals innervating the cortex. Alterations in mood, cognition, and impulse control associated with these changes might contribute to sustain MDMA use. The reversibility of these changes upon abstinence remains to be firmly established.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22353758      PMCID: PMC3327851          DOI: 10.1038/npp.2011.332

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  46 in total

1.  Comparative evaluation in nonhuman primates of five PET radiotracers for imaging the serotonin transporters: [11C]McN 5652, [11C]ADAM, [11C]DASB, [11C]DAPA, and [11C]AFM.

Authors:  Yiyun Huang; Dah-Ren Hwang; Raj Narendran; Yasuhiko Sudo; Rano Chatterjee; Sung-A Bae; Osama Mawlawi; Lawrence S Kegeles; Alan A Wilson; Hank F Kung; Marc Laruelle
Journal:  J Cereb Blood Flow Metab       Date:  2002-11       Impact factor: 6.200

2.  In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652.

Authors:  R V Parsey; L S Kegeles; D R Hwang; N Simpson; A Abi-Dargham; O Mawlawi; M Slifstein; R L Van Heertum; J J Mann; M Laruelle
Journal:  J Nucl Med       Date:  2000-09       Impact factor: 10.057

3.  Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users.

Authors:  A C Parrott; T Buchanan; A B Scholey; T Heffernan; J Ling; J Rodgers
Journal:  Hum Psychopharmacol       Date:  2002-08       Impact factor: 1.672

4.  Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users.

Authors:  D M Semple; K P Ebmeier; M F Glabus; R E O'Carroll; E C Johnstone
Journal:  Br J Psychiatry       Date:  1999-07       Impact factor: 9.319

5.  Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB.

Authors:  S Houle; N Ginovart; D Hussey; J H Meyer; A A Wilson
Journal:  Eur J Nucl Med       Date:  2000-11

6.  Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET.

Authors:  Ralph Buchert; Rainer Thomasius; Bruno Nebeling; Kay Petersen; Jost Obrocki; Lars Jenicke; Florian Wilke; Lutz Wartberg; Pavlina Zapletalova; Malte Clausen
Journal:  J Nucl Med       Date:  2003-03       Impact factor: 10.057

7.  Regional and subcellular localization in human brain of [3H]paroxetine binding, a marker of serotonin uptake sites.

Authors:  M Laruelle; M A Vanisberg; J M Maloteaux
Journal:  Biol Psychiatry       Date:  1988-07       Impact factor: 13.382

8.  Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons.

Authors:  L Reneman; J Booij; K de Bruin; J B Reitsma; F A de Wolff; W B Gunning; G J den Heeten; W van den Brink
Journal:  Lancet       Date:  2001-12-01       Impact factor: 79.321

9.  Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.

Authors:  A A Wilson; N Ginovart; M Schmidt; J H Meyer; P G Threlkeld; S Houle
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

10.  The acute and chronic effects of MDMA ("ecstasy") on cortical 5-HT2A receptors in rat and human brain.

Authors:  Liesbeth Reneman; Erik Endert; Kora de Bruin; Jules Lavalaye; Mathijs G Feenstra; Freek A de Wolff; Jan Booij
Journal:  Neuropsychopharmacology       Date:  2002-03       Impact factor: 7.853

View more
  18 in total

1.  fNIRS suggests increased effort during executive access in ecstasy polydrug users.

Authors:  C A Roberts; C Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2014-11-14       Impact factor: 4.530

Review 2.  Brain serotonin function in MDMA (ecstasy) users: evidence for persisting neurotoxicity.

Authors:  Margaret M Benningfield; Ronald L Cowan
Journal:  Neuropsychopharmacology       Date:  2013-01       Impact factor: 7.853

Review 3.  The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Authors:  Yosta Vegting; Liesbeth Reneman; Jan Booij
Journal:  Psychopharmacology (Berl)       Date:  2016-08-28       Impact factor: 4.530

4.  Repeated exposure to MDMA triggers long-term plasticity of noradrenergic and serotonergic neurons.

Authors:  C Lanteri; E L Doucet; S J Hernández Vallejo; G Godeheu; A-C Bobadilla; L Salomon; L Lanfumey; J-P Tassin
Journal:  Mol Psychiatry       Date:  2013-08-20       Impact factor: 15.992

Review 5.  MDMA for the treatment of mood disorder: all talk no substance?

Authors:  Rachel Patel; Daniel Titheradge
Journal:  Ther Adv Psychopharmacol       Date:  2015-06

6.  The acute effects of MDMA and ethanol administration on electrophysiological correlates of performance monitoring in healthy volunteers.

Authors:  D B Spronk; G J H Dumont; R J Verkes; E R A De Bruijn
Journal:  Psychopharmacology (Berl)       Date:  2014-04-26       Impact factor: 4.530

7.  Commentary on Boileau et al. (2013): Distinguishing D2/D3 dopaminergic contributions to addictions.

Authors:  Marc N Potenza; Arthur L Brody
Journal:  Addiction       Date:  2013-05       Impact factor: 6.526

Review 8.  Integrated treatment of substance use and psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley
Journal:  Soc Work Public Health       Date:  2013

Review 9.  Neuroimaging of reward mechanisms in Gambling disorder: an integrative review.

Authors:  Luke Clark; Isabelle Boileau; Martin Zack
Journal:  Mol Psychiatry       Date:  2018-09-13       Impact factor: 15.992

Review 10.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.